The short answer
Melatonin can cause drowsiness, so review it with your treatment team before combining it with lofexidine. Added impairment is a reasonable precaution, but its size has not been measured for this pair.
What this answer covers
Oral melatonin; the inspected Circadin information concerns a licensed prolonged-release preparation and does not define every supplement.
- Supplement or preparation
- Melatonin
- Medication ingredient
- lofexidine
Two sources support checking alertness
The melatonin product information warns about drowsiness, while lofexidine labeling warns that other sedating products can have stronger effects during co-use. Neither source quantifies this exact combination.
Sleep benefit and daytime impairment differ
A product intended to help sleep is not automatically appropriate during withdrawal treatment. The melatonin label describes sleep benefits for its studied population, but also warns about driving impairment in affected people.
Do not borrow a timing rule from another product
The bedtime directions for prolonged-release melatonin belong to that preparation. They do not establish a safe interval from lofexidine. Have the team review the formulation and your prescribed dosing schedule.
Protect alertness during withdrawal treatment
Do not drive or use machinery if drowsy, and follow the treatment team’s advice until you know how lofexidine affects you. Tell the team about alcohol and all sleep products. Contact them if sedation becomes troublesome; lofexidine should not be abruptly stopped without a plan.
Evidence and practical considerations
Side effects & toxicity
Conditional combined-impairment caution is supported; exact-pair effects and protective timing remain unmeasured.
- Exact scope
- Oral melatonin; the inspected Circadin information concerns a licensed prolonged-release preparation and does not define every supplement. with Oral lofexidine for adult opioid withdrawal; label section 11 supports hydrochloride-to-active-moiety identity.
- Medication form and route
- oral supplement unless clinician-directed electrolyte correction requires another route
- Timing or duration
- Lofexidine course is symptom-guided up to 14 days; longer supplement studies do not establish acute co-use safety.
What remains uncertain
- Different melatonin products and sleep conditions may respond differently; no lofexidine trial identified.
Factors that may matter: exact preparation; blood pressure and pulse; kidney function; other medicines; baseline electrolyte status or alertness.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Adults receiving treatment for opioid withdrawal symptoms.
Can cause hypotension, bradycardia, syncope and sedation. Avoid medicines lowering pulse or pressure; potentiates benzodiazepine CNS depression and is expected to potentiate other sedating drugs. Correct hypokalemia/hypomagnesemia first and monitor ECG at initiation in those patients because lofexidine prolongs QT. Abrupt discontinuation can raise blood pressure.
How this applies: RxNorm 28863 IN maps to this SPL; section 11 confirms salt-to-active-moiety identity. Applies to prescribed oral lofexidine for adult opioid withdrawal, not another alpha-2 agonist.
Does not establish supplement depletion, automatic supplementation, exact botanical interaction rates or a safe supplement spacing interval.
Source 2: product label
medicines.org.uk · Source check Sep 10, 2026
Population: People considering the specified supplement.
Can cause drowsiness and impair driving. Bedtime instructions are specific to this prolonged-release preparation. Co-administration with zolpidem increased impairment, but that is a different medicine.
How this applies: Preparation-specific context; not a directly measured lofexidine interaction.
No lofexidine study. Findings with zolpidem or this licensed formulation cannot define every melatonin product or a protective interval.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Inspected sources applied to exact current available claim; no clinical review asserted. | |
| Research summary published |
Article revision: 0d489ad087fefd57
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.